F S&P 500
5,356.25 +28.25 (+0.53%) F Dow Jones
39,824.00 +41.00 (+0.10%) F Nasdaq
18,952.50 +165.75 (+0.88%) E-mini Russell 2000 Index Futur
2,095.20 +6.10 (+0.29%) Petróleo
78.24 +0.67 (+0.86%) Oro
2,368.00 -24.90 (-1.04%)
BioCryst Pharmaceuticals, Inc. (BO1.F)
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919 859 1302
https://www.biocryst.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 536
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Jon P. Stonehouse | CEO, President & Executive Director | 1.14M | 596.19k | 1961 |
| Mr. Anthony J. Doyle | Senior VP, CFO & Interim Principal Accounting Officer | 779.33k | N/D | 1980 |
| Ms. Alane P. Barnes | Senior VP, Chief Legal Officer & Corporate Secretary | 732.18k | N/D | 1966 |
| Dr. Helen M. Thackray FAAP, M.D. | Chief Research & Development Officer | 899.3k | N/D | 1968 |
| Mr. Charles K. Gayer | Senior VP & Chief Commercial Officer | 731.6k | N/D | 1971 |
| Mr. John D. Bluth | Chief Communications Officer | N/D | N/D | 1973 |
| Ms. Stephanie Angelini | Chief People Officer | N/D | N/D | N/D |
| Dr. William P. Sheridan MBBS | Chief Development Officer & Interim Chief Medical Officer | 722.36k | 4.05M | 1955 |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer | 637.01k | 1.15M | 1953 |
| Ms. Jinky Ang Rosselli | Chief Data & Insights Officer | N/D | N/D | N/D |
Descripción
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Gestión corporativa
La calificación ISS Governance QuickScore de BioCryst Pharmaceuticals, Inc. a partir del 1 de mayo de 2024 es 6. Las puntuaciones principales son Auditoría: 8; Junta: 3; Derechos del accionista: 8; Compensación: 5.
